Mark Adamchak
Bionano GenomicsAbout Mark Adamchak
Mark Adamchak is Bionano Genomics’ Principal Accounting Officer (PAO), age 45, and serves concurrently as Vice President, Accounting & Finance; he was appointed PAO effective September 18, 2024 and has led Bionano’s accounting function since 2018, including through its August 2018 IPO . He is a licensed CPA with a B.B.A. in Accounting from James Madison University and previously held financial leadership roles at SAIC, Intuit, and Pathway Genomics, and began his career as an auditor at KPMG . As PAO, he signs SOX certifications and 10‑Q filings alongside the CEO, reflecting responsibility for disclosure controls and internal control over financial reporting .
Past Roles
| Organization | Role | Years | Strategic Impact |
|---|---|---|---|
| Bionano Genomics | Controller | Jun 2018–2021 | Led accounting through the company’s IPO in Aug 2018 . |
| Bionano Genomics | VP, Accounting (and later VP, Accounting & Finance) | Oct 2021–present | Continued leadership of accounting/finance; promoted to PAO in 2024 . |
| Bionano Genomics | Principal Accounting Officer | Sep 18, 2024–present | Elevated to PAO; signs 10‑Q certifications and filings . |
External Roles
| Organization | Role | Years | Strategic Impact |
|---|---|---|---|
| SAIC | Financial leadership roles | Not disclosed | Prior corporate finance leadership experience . |
| Intuit | Financial leadership roles | Not disclosed | Prior corporate finance leadership experience . |
| Pathway Genomics | Financial leadership roles | Not disclosed | Prior life sciences finance experience . |
| KPMG | Auditor | Not disclosed | Foundational audit training; CPA credential . |
Fixed Compensation
No individual compensation disclosure for Adamchak in the latest proxy (he is not a named executive officer). Company-wide executive compensation framework and peer benchmarking are disclosed for named executive officers but do not specify Adamchak’s base salary or bonus terms .
Performance Compensation
No performance bonus targets or payouts are individually disclosed for Adamchak. For context, the Compensation Committee withheld performance-based bonuses for named executive officers in 2023 and 2024; retention cash bonuses in 2024 were paid to named executives upon creation of a CPT I code for OGM—these do not attribute to Adamchak .
Equity Ownership & Alignment
- Hedging and pledging of company stock are prohibited for all officers under Bionano’s Insider Trading Policy, which mitigates misalignment and leverage-related risks .
- Stock ownership guidelines for officers are not disclosed; no pledges reported for Adamchak.
| Item | Detail |
|---|---|
| Beneficial ownership (combined footnote for GC and PAO) | 200 shares of common stock held by Jonathan Dixon and Mark Adamchak; 1,144 shares issuable upon exercise of options exercisable within 60 days by Jonathan Dixon and Mark Adamchak (individual breakdown not provided) . |
| Insider transactions | Form 4 filings by Adamchak on Oct 1, 2024, Mar 14, 2025, and Jun 3, 2025 (statement of changes in beneficial ownership). Transaction-level quantities/prices should be taken from the forms directly . |
| Certifications | Signed 10‑Q as PAO and co-signed SOX §906 certification with CEO (Nov 14, 2024) . |
Note: The beneficial ownership table in the proxy aggregates Jonathan Dixon and Mark Adamchak in a footnote; the company did not publish an individual breakdown for Adamchak in that table .
Employment Terms
| Term | Detail |
|---|---|
| Appointment | Board appointed Adamchak (VP, Accounting & Finance) as Principal Accounting Officer effective Sep 18, 2024 . |
| Role scope | PAO responsibilities include disclosure controls and ICFR oversight; signs Section 302/906 certifications with CEO on periodic reports . |
| Contract/severance | No individual employment agreement, severance, or change‑in‑control terms are disclosed for Adamchak; such terms are disclosed only for named executive officers . |
| Clawback policy | Company implemented a Dodd‑Frank‑compliant clawback policy, in addition to SOX §304 reimbursement obligations for CEO/CFO; applies at the company level . |
| Insider policy | Hedging, short sales, margining, and pledging are prohibited for officers . |
Investment Implications
- Alignment and selling pressure: Prohibitions on hedging/pledging reduce misalignment risk; however, Adamchak’s recurring Form 4 activity indicates ongoing changes in beneficial ownership. Transaction specifics (sales vs. acquisitions) and resulting selling pressure should be assessed directly from the filed forms for precise sizing and timing .
- Retention/execution risk: Following the CFO’s departure in Sep 2024, the CEO took on Principal Financial Officer duties and Adamchak assumed PAO responsibilities, increasing concentration of finance leadership and reliance on Adamchak’s continuity; this raises execution risk if turnover occurs in finance roles . His long tenure since 2018 and expanded responsibilities suggest strong internal knowledge, which supports continuity .
- Governance and controls: Adamchak’s SOX certifications and role in ICFR/disclosure controls underscore accountability for reporting quality; adverse changes in control effectiveness would be reflected in SEC filings and certifications, providing timely signals to investors .
For trading signals and a fuller skin‑in‑the‑game assessment, pull detailed grant, vesting, and transaction line items from Adamchak’s Form 4 filings (quantities, transaction codes, prices) and track upcoming vesting dates against blackout windows and liquidity needs.